GHP Investment Advisors Inc. raised its holdings in STERIS plc (NYSE:STE - Free Report) by 3.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,484 shares of the medical equipment provider's stock after acquiring an additional 2,186 shares during the period. GHP Investment Advisors Inc. owned approximately 0.06% of STERIS worth $13,935,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. raised its stake in STERIS by 5.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 8,951 shares of the medical equipment provider's stock valued at $2,029,000 after purchasing an additional 431 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of STERIS in the 1st quarter worth $650,000. Harvey Investment Co. LLC raised its position in shares of STERIS by 18.3% during the 1st quarter. Harvey Investment Co. LLC now owns 66,660 shares of the medical equipment provider's stock valued at $15,108,000 after buying an additional 10,300 shares in the last quarter. Running Oak Capital LLC lifted its holdings in shares of STERIS by 12.1% during the 1st quarter. Running Oak Capital LLC now owns 66,459 shares of the medical equipment provider's stock worth $15,063,000 after acquiring an additional 7,183 shares during the last quarter. Finally, Suncoast Equity Management lifted its holdings in shares of STERIS by 16.7% during the 1st quarter. Suncoast Equity Management now owns 4,155 shares of the medical equipment provider's stock worth $942,000 after acquiring an additional 595 shares during the last quarter. Institutional investors own 94.69% of the company's stock.
STERIS Price Performance
STE opened at $236.95 on Tuesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.96 and a quick ratio of 1.39. The stock's 50 day simple moving average is $234.89 and its 200 day simple moving average is $223.58. The firm has a market cap of $23.31 billion, a price-to-earnings ratio of 38.22 and a beta of 0.94. STERIS plc has a 1 year low of $200.98 and a 1 year high of $252.79.
STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.15. STERIS had a net margin of 11.26% and a return on equity of 14.21%. The firm had revenue of $1.48 billion for the quarter, compared to analysts' expectations of $1.47 billion. During the same quarter last year, the business earned $2.58 earnings per share. The business's revenue was up 5.7% on a year-over-year basis. As a group, analysts predict that STERIS plc will post 9.08 earnings per share for the current year.
STERIS Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Tuesday, June 10th. STERIS's payout ratio is 36.77%.
Analyst Ratings Changes
STE has been the topic of a number of research analyst reports. Citigroup reissued an "outperform" rating on shares of STERIS in a research note on Friday, May 16th. Jefferies Financial Group assumed coverage on STERIS in a research report on Thursday, May 29th. They set a "hold" rating and a $263.00 price objective on the stock. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 14th. Morgan Stanley upped their target price on STERIS from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research note on Monday, May 19th. Finally, Needham & Company LLC reissued a "hold" rating on shares of STERIS in a research note on Monday, April 7th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, STERIS currently has an average rating of "Moderate Buy" and a consensus target price of $263.83.
Check Out Our Latest Report on STERIS
Insider Transactions at STERIS
In other STERIS news, SVP Cary L. Majors sold 12,828 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares in the company, valued at approximately $2,843,909.76. This represents a 53.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel A. Carestio sold 17,626 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $242.56, for a total transaction of $4,275,362.56. Following the completion of the sale, the chief executive officer now directly owns 51,385 shares of the company's stock, valued at approximately $12,463,945.60. This represents a 25.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company's stock.
STERIS Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Recommended Stories
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
